Akeso flags Phase III overall survival data for ivonescimab in biliary tract cancer

Akeso said it has positive overall survival results from a Phase III study of ivonescimab in first-line advanced biliary tract cancer. The company has not yet presented the data and said they are scheduled as a late-breaking oral at ESMO 2026 in Madrid on Oct. 25, 2026.